Bioxytran (BIXT) Interest & Investment Income (2011)
Bioxytran (BIXT) posted Interest & Investment Income of $2052.0 for Q3 2011.
Bioxytran (BIXT) Interest & Investment Income (2011) Analysis & Trends
Bioxytran has reported Interest & Investment Income for 1 years, with the latest figure at $2052.0 in Q3 2011.
- Quarterly Interest & Investment Income changed N/A year-over-year to $2052.0 in Q3 2011, while the trailing twelve-month figure through Mar 2012 was $2052.0 (changed N/A YoY) and the FY2011 annual result came in at $2052.0, up 121.84% from the prior year.
- Interest & Investment Income held at $2052.0 in Q3 2011 per BIXT's latest filing.
- Over five years, Interest & Investment Income peaked at $2052.0 in Q3 2011 and troughed at $2052.0 in Q3 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2011 | 2,052.00 |